Abstract
The antidiabetic effect of the dipeptidyl peptidase 4 (DPP-4) inhibitor saxagliptin depends on the prolongation of action of the 2 incretin hormones: glucagon like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) by preventing their rapid degradation by the enzyme DPP-4. The use of saxagliptin (5 mg/d) is associated with mean reduction in glycosylated hemoglobin (HbA1c) levels ranging from 0.5% to 0.9% compared with baseline and 0.6 to 0.8% compared with placebo after 24 weeks of therapy. The main advantages of saxagliptin are the low risk of hypoglycemia, the neutral effect on body weight, the simplicity of use, and reassuring short-term safety profile. However, its mild-to-moderate efficacy, the lack of long-term safety and efficacy data, and relatively high cost represent its major limitations. Overall, saxagliptin may be a useful second agent for patients with type 2 diabetes who are not optimally controlled on metformin. This drug can also be used as monotherapy in patients with mild hyperglycemia who cannot tolerate metformin or a sulfonylurea (SU).
Keywords: Saxagliptin, DPP-4 inhibitors, incretins, type 2 diabetes
Current Drug Therapy
Title: Appraisal of Saxagliptin as Treatment of Type 2 Diabetes
Volume: 5 Issue: 2
Author(s): Nasser Mikhail and Dennis Cope
Affiliation:
Keywords: Saxagliptin, DPP-4 inhibitors, incretins, type 2 diabetes
Abstract: The antidiabetic effect of the dipeptidyl peptidase 4 (DPP-4) inhibitor saxagliptin depends on the prolongation of action of the 2 incretin hormones: glucagon like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) by preventing their rapid degradation by the enzyme DPP-4. The use of saxagliptin (5 mg/d) is associated with mean reduction in glycosylated hemoglobin (HbA1c) levels ranging from 0.5% to 0.9% compared with baseline and 0.6 to 0.8% compared with placebo after 24 weeks of therapy. The main advantages of saxagliptin are the low risk of hypoglycemia, the neutral effect on body weight, the simplicity of use, and reassuring short-term safety profile. However, its mild-to-moderate efficacy, the lack of long-term safety and efficacy data, and relatively high cost represent its major limitations. Overall, saxagliptin may be a useful second agent for patients with type 2 diabetes who are not optimally controlled on metformin. This drug can also be used as monotherapy in patients with mild hyperglycemia who cannot tolerate metformin or a sulfonylurea (SU).
Export Options
About this article
Cite this article as:
Mikhail Nasser and Cope Dennis, Appraisal of Saxagliptin as Treatment of Type 2 Diabetes, Current Drug Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157488510791065049
DOI https://dx.doi.org/10.2174/157488510791065049 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiangiogenesis Drug Design: Multiple Pathways Targeting Tumor Vasculature
Current Medicinal Chemistry Bone Marrow Stem Cell Therapy for Myocardial Angiogenesis
Current Vascular Pharmacology Editorial [ Hot Topic: Cancer Therapy-Related Cardiotoxicity (Guest Editor: Maysa Abu-Khalaf and Feras Bader)]
Current Cardiology Reviews Pharmacological manipulation of peripheral vascular resistance in special clinical situations after pediatric cardiac surgery
Current Vascular Pharmacology From Dual Peroxisome Proliferator Activated Receptor Agonists to Selective Peroxisome Proliferator Activated Receptor Modulators
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Connexins as Precocious Markers and Molecular Targets for Chemical and Pharmacological Agents in Carcinogenesis
Current Medicinal Chemistry Therapeutic Potential of Inhibiting Brutons Tyrosine Kinase, (BTK)
Current Pharmaceutical Design Revolutionary Impact of Nanodrug Delivery on Neuroscience
Current Neuropharmacology Myocardial Protection Against Ischemia-Reperfusion Injury: Novel Approaches in Maintaining Homeostatic Stability in Blood
Recent Patents on Cardiovascular Drug Discovery Tumor Angiogenesis: A Potential Target In Cancer Control by Phytochemicals
Current Cancer Drug Targets Characterization of Adipose-Derived Stem Cells: An Update
Current Stem Cell Research & Therapy Applied Proteomics in Companion Animal Medicine
Current Proteomics Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets The Involvement of PPARs in the Causes, Consequences and Mechanisms for Correction of Cardiac Lipotoxicity and Oxidative Stress
Current Molecular Pharmacology The Effect of Borage (Echium amoenum) on the Mouse Heart and Hematology Parameters
Cardiovascular & Hematological Disorders-Drug Targets Mitochondrial Functionality and Chemical Compound Action on Sperm Function
Current Medicinal Chemistry The Opioid Receptor Independent Actions of Kappa Receptor Agonists in the Cardiovascular System
Current Pharmaceutical Design New Therapies for Patients with Chronic Lymphocytic Leukemia
Current Cancer Therapy Reviews Fibrates in the Chemical Action of Daunorubicin
Current Cancer Drug Targets Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets